To NASDAQ OMX Copenhagen A/S
Announcement no. 14-14 / Copenhagen, June 30, 2014
The board of directors of Topotarget A/S has resolved to increase the company’s share capital by nominal DKK 2,473,998 as a consequence of the exercise of warrants granted to employees and board member. The capital increase corresponds to 1.7% of Topotarget's existing share capital.
The new shares are issued to warrant holders without pre-emption rights for Topotarget's existing shareholders. The new shares will rank pari passu in all respects with the existing Topotarget shares. The new shares will be negotiable instruments, and no restrictions will apply to their transferability. No shares, including the new shares, carry or will carry any special rights. Rights conferred by the new shares will apply from the time when the capital increase is registered with the Danish Business Authority.
The shares are all subscribed in cash at the following subscription prices per share of nominally DKK 1 each: 178,998 shares at DKK 3.20, 555,000 shares at DKK 2.02, 510,000 shares at DKK 2.75, 715,000 shares at DKK 2.93, 455,000 shares at DKK 3.4, 50,000 shares at DKK 1.9, and 10,000 shares at DKK 3.31.
After the capital increase, the company's share capital will be nominal DKK 145,791,112 divided into 145,791,112 shares of nom. value DKK 1 each.
The capital increase is expected to be registered with the Danish Business Authority tomorrow and the new shares will be admitted for trading and official listing on NASDAQ OMX Copenhagen A/S expectedly on Wednesday, July 3 2014.
For further information, please contact:
Anders Vadsholt, CEO – direct: +45 39178345
Topotarget (NASDAQ OMX: TOPO) is a Danish-based biopharmaceutical company headquartered in Copenhagen, Denmark, dedicated to the clinical development and registration of oncology products. In collaboration with Spectrum Pharmaceuticals, Inc., Topotarget focuses on the development of its lead drug candidate, belinostat, which has shown positive results in the treatment of hematological malignancies and solid tumors, obtained by both mono- and combination therapy. For more information, please refer to www.topotarget.com.
Topotarget Safe Harbor Statement
This announcement may contain forward-looking statements, including statements about Topotarget A/S’ expectations to the progression of Topotarget A/S’ clinical pipeline and with respect to cash burn guidance. Such statements are subject to risks and uncertainties of which many are outside the control of Topotarget A/S, and which could cause actual results to differ materially from those described. Topotarget A/S disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by Danish law.